Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro
Peptide YY (PYY) is an endogenous gut hormone that inhibits the growth of certain cancers. Adenocarcinoma of the esophagus usually arises from Barrett's esophagus. We hypothesized that treatment of Barrett's adenocarcinoma with PYY would result in decreased proliferation. Barrett's ca...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 2004-11, Vol.188 (5), p.516-519 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 519 |
|---|---|
| container_issue | 5 |
| container_start_page | 516 |
| container_title | The American journal of surgery |
| container_volume | 188 |
| creator | McFadden, David W. Riggs, Dale R. Jackson, Barbara J. Vona-Davis, Linda |
| description | Peptide YY (PYY) is an endogenous gut hormone that inhibits the growth of certain cancers. Adenocarcinoma of the esophagus usually arises from Barrett's esophagus. We hypothesized that treatment of Barrett's adenocarcinoma with PYY would result in decreased proliferation.
Barrett's cancer cell lines (BIC and SEG-1) were treated with PYY (3-36) at 500 pmol/mL. Viability was measured by MTT at 24 and 72 hours. Apoptosis and necrosis was evaluated by flow cytometry.
PYY reduced proliferation in SEG-1 cells at 24 hours (21.2% ± 3.4%,
P |
| doi_str_mv | 10.1016/j.amjsurg.2004.07.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67089719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961004003393</els_id><sourcerecordid>2729455241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-86c47a499c60230de8adf84858b4d1b840e622aeb3b59eddfe141c07f173cca53</originalsourceid><addsrcrecordid>eNqF0U2L1TAUBuAginNn9CcoAXFctZ60aZquRAe_YFAXuphVSJPTe1Pa5pqkI_57M9zCgAtdhcDzHg7nJeQZg5IBE6_HUs9jXMO-rAB4CW0J0D0gOybbrmBS1g_JDgCqohMMzsh5jGP-Msbrx-SMNQ0XjWA78uUbHpOzSG9uqFsOrncp0nRAug_-VzpQP9B3OgRM6VWkGP3xoPeoJ6otLt7oYNziZ52j9Nal4J-QR4OeIj7d3gvy48P771efiuuvHz9fvb0uDOdtKqQwvNW864yAqgaLUttBctnInlvWSw4oqkpjX_dNh9YOyDgz0A6srY3RTX1BLk9zj8H_XDEmNbtocJr0gn6NSrQgu5Z1Gb74C45-DUveTTHOedPJKs_8l4KaVZDPVmXVnJQJPsaAgzoGN-vwOyN1V4oa1VaKuitFQatyKTn3fJu-9jPa-9TWQgYvN6Cj0dMQ9GJcvHeiZiAEz-7NyWE-7a3DoKJxuBi0LqBJynr3n1X-ABzVq7U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1031201432</pqid></control><display><type>article</type><title>Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>McFadden, David W. ; Riggs, Dale R. ; Jackson, Barbara J. ; Vona-Davis, Linda</creator><creatorcontrib>McFadden, David W. ; Riggs, Dale R. ; Jackson, Barbara J. ; Vona-Davis, Linda</creatorcontrib><description>Peptide YY (PYY) is an endogenous gut hormone that inhibits the growth of certain cancers. Adenocarcinoma of the esophagus usually arises from Barrett's esophagus. We hypothesized that treatment of Barrett's adenocarcinoma with PYY would result in decreased proliferation.
Barrett's cancer cell lines (BIC and SEG-1) were treated with PYY (3-36) at 500 pmol/mL. Viability was measured by MTT at 24 and 72 hours. Apoptosis and necrosis was evaluated by flow cytometry.
PYY reduced proliferation in SEG-1 cells at 24 hours (21.2% ± 3.4%,
P <0.001) and 72 hours (14.2% ± 6.2%,
P <0.001). In the BIC cells, growth was inhibited by 7.9% ± 7.0%,
P = 0.021 after 72 hours. PYY increased late apoptotic activity in SEG-1 cells by 31%,
P = 0.014.
This is the first report of antiproliferative effects of PYY against Barrett's carcinoma in vitro. Reductions in cell growth appear to be mediated by proapoptotic mechanisms. Further investigation of PYY in the treatment of Barrett's adenocarcinoma is warranted.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2004.07.009</identifier><identifier>PMID: 15546561</identifier><identifier>CODEN: AJSUAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adenocarcinoma - pathology ; Analysis of Variance ; Apoptosis ; Apoptosis - drug effects ; Barrett Esophagus - pathology ; Barrett's adenocarcinoma ; Biological and medical sciences ; Breast cancer ; Cancer therapies ; Cell culture ; Cell growth ; Cell Proliferation - drug effects ; Cellular inhibition ; Chemotherapy ; Colon ; Cytokines ; Esophageal Neoplasms - pathology ; Flow cytometry ; General aspects ; Humans ; In Vitro Techniques ; Medical sciences ; Mutation ; Peptide YY ; Peptide YY - pharmacology ; Probability ; Proteins ; Risk Factors ; Sensitivity and Specificity ; Tumor Cells, Cultured ; Tumors ; Vitamin E</subject><ispartof>The American journal of surgery, 2004-11, Vol.188 (5), p.516-519</ispartof><rights>2004 Excerpta Medica Inc.</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jan 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-86c47a499c60230de8adf84858b4d1b840e622aeb3b59eddfe141c07f173cca53</citedby><cites>FETCH-LOGICAL-c447t-86c47a499c60230de8adf84858b4d1b840e622aeb3b59eddfe141c07f173cca53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002961004003393$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16310664$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15546561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McFadden, David W.</creatorcontrib><creatorcontrib>Riggs, Dale R.</creatorcontrib><creatorcontrib>Jackson, Barbara J.</creatorcontrib><creatorcontrib>Vona-Davis, Linda</creatorcontrib><title>Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Peptide YY (PYY) is an endogenous gut hormone that inhibits the growth of certain cancers. Adenocarcinoma of the esophagus usually arises from Barrett's esophagus. We hypothesized that treatment of Barrett's adenocarcinoma with PYY would result in decreased proliferation.
Barrett's cancer cell lines (BIC and SEG-1) were treated with PYY (3-36) at 500 pmol/mL. Viability was measured by MTT at 24 and 72 hours. Apoptosis and necrosis was evaluated by flow cytometry.
PYY reduced proliferation in SEG-1 cells at 24 hours (21.2% ± 3.4%,
P <0.001) and 72 hours (14.2% ± 6.2%,
P <0.001). In the BIC cells, growth was inhibited by 7.9% ± 7.0%,
P = 0.021 after 72 hours. PYY increased late apoptotic activity in SEG-1 cells by 31%,
P = 0.014.
This is the first report of antiproliferative effects of PYY against Barrett's carcinoma in vitro. Reductions in cell growth appear to be mediated by proapoptotic mechanisms. Further investigation of PYY in the treatment of Barrett's adenocarcinoma is warranted.</description><subject>Adenocarcinoma - pathology</subject><subject>Analysis of Variance</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Barrett Esophagus - pathology</subject><subject>Barrett's adenocarcinoma</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cell culture</subject><subject>Cell growth</subject><subject>Cell Proliferation - drug effects</subject><subject>Cellular inhibition</subject><subject>Chemotherapy</subject><subject>Colon</subject><subject>Cytokines</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Flow cytometry</subject><subject>General aspects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Peptide YY</subject><subject>Peptide YY - pharmacology</subject><subject>Probability</subject><subject>Proteins</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><subject>Vitamin E</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0U2L1TAUBuAginNn9CcoAXFctZ60aZquRAe_YFAXuphVSJPTe1Pa5pqkI_57M9zCgAtdhcDzHg7nJeQZg5IBE6_HUs9jXMO-rAB4CW0J0D0gOybbrmBS1g_JDgCqohMMzsh5jGP-Msbrx-SMNQ0XjWA78uUbHpOzSG9uqFsOrncp0nRAug_-VzpQP9B3OgRM6VWkGP3xoPeoJ6otLt7oYNziZ52j9Nal4J-QR4OeIj7d3gvy48P771efiuuvHz9fvb0uDOdtKqQwvNW864yAqgaLUttBctnInlvWSw4oqkpjX_dNh9YOyDgz0A6srY3RTX1BLk9zj8H_XDEmNbtocJr0gn6NSrQgu5Z1Gb74C45-DUveTTHOedPJKs_8l4KaVZDPVmXVnJQJPsaAgzoGN-vwOyN1V4oa1VaKuitFQatyKTn3fJu-9jPa-9TWQgYvN6Cj0dMQ9GJcvHeiZiAEz-7NyWE-7a3DoKJxuBi0LqBJynr3n1X-ABzVq7U</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>McFadden, David W.</creator><creator>Riggs, Dale R.</creator><creator>Jackson, Barbara J.</creator><creator>Vona-Davis, Linda</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro</title><author>McFadden, David W. ; Riggs, Dale R. ; Jackson, Barbara J. ; Vona-Davis, Linda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-86c47a499c60230de8adf84858b4d1b840e622aeb3b59eddfe141c07f173cca53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Analysis of Variance</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Barrett Esophagus - pathology</topic><topic>Barrett's adenocarcinoma</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cell culture</topic><topic>Cell growth</topic><topic>Cell Proliferation - drug effects</topic><topic>Cellular inhibition</topic><topic>Chemotherapy</topic><topic>Colon</topic><topic>Cytokines</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Flow cytometry</topic><topic>General aspects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Peptide YY</topic><topic>Peptide YY - pharmacology</topic><topic>Probability</topic><topic>Proteins</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><topic>Vitamin E</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McFadden, David W.</creatorcontrib><creatorcontrib>Riggs, Dale R.</creatorcontrib><creatorcontrib>Jackson, Barbara J.</creatorcontrib><creatorcontrib>Vona-Davis, Linda</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McFadden, David W.</au><au>Riggs, Dale R.</au><au>Jackson, Barbara J.</au><au>Vona-Davis, Linda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>188</volume><issue>5</issue><spage>516</spage><epage>519</epage><pages>516-519</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><coden>AJSUAB</coden><abstract>Peptide YY (PYY) is an endogenous gut hormone that inhibits the growth of certain cancers. Adenocarcinoma of the esophagus usually arises from Barrett's esophagus. We hypothesized that treatment of Barrett's adenocarcinoma with PYY would result in decreased proliferation.
Barrett's cancer cell lines (BIC and SEG-1) were treated with PYY (3-36) at 500 pmol/mL. Viability was measured by MTT at 24 and 72 hours. Apoptosis and necrosis was evaluated by flow cytometry.
PYY reduced proliferation in SEG-1 cells at 24 hours (21.2% ± 3.4%,
P <0.001) and 72 hours (14.2% ± 6.2%,
P <0.001). In the BIC cells, growth was inhibited by 7.9% ± 7.0%,
P = 0.021 after 72 hours. PYY increased late apoptotic activity in SEG-1 cells by 31%,
P = 0.014.
This is the first report of antiproliferative effects of PYY against Barrett's carcinoma in vitro. Reductions in cell growth appear to be mediated by proapoptotic mechanisms. Further investigation of PYY in the treatment of Barrett's adenocarcinoma is warranted.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15546561</pmid><doi>10.1016/j.amjsurg.2004.07.009</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 2004-11, Vol.188 (5), p.516-519 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67089719 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma - pathology Analysis of Variance Apoptosis Apoptosis - drug effects Barrett Esophagus - pathology Barrett's adenocarcinoma Biological and medical sciences Breast cancer Cancer therapies Cell culture Cell growth Cell Proliferation - drug effects Cellular inhibition Chemotherapy Colon Cytokines Esophageal Neoplasms - pathology Flow cytometry General aspects Humans In Vitro Techniques Medical sciences Mutation Peptide YY Peptide YY - pharmacology Probability Proteins Risk Factors Sensitivity and Specificity Tumor Cells, Cultured Tumors Vitamin E |
| title | Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peptide%20YY%20inhibits%20the%20growth%20of%20Barrett's%20esophageal%20adenocarcinoma%20in%20vitro&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=McFadden,%20David%20W.&rft.date=2004-11-01&rft.volume=188&rft.issue=5&rft.spage=516&rft.epage=519&rft.pages=516-519&rft.issn=0002-9610&rft.eissn=1879-1883&rft.coden=AJSUAB&rft_id=info:doi/10.1016/j.amjsurg.2004.07.009&rft_dat=%3Cproquest_cross%3E2729455241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1031201432&rft_id=info:pmid/15546561&rft_els_id=S0002961004003393&rfr_iscdi=true |